Abstract
Fabry disease (FD) is an X-linked lysosomal storage disorder in which glycosphingolipids accumulate in tissues, causing multisystem disease. FD is associated with mild tricuspid, aortic, and mitral valvular heart disease (VHD).1-3 The burden of VHD in the aging FD population treated with modern medical therapy, including enzyme replacement therapy (ERT), substrate reduction therapy, and aggressive control of cardiovascular comorbidities, is unknown. We describe the burden of VHD in a multicenter cohort of patients with FD with access to contemporary FD therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of the American Society of Echocardiography
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.